A Phase II Stydy of Bevacizumab Plus Erlotinib in Patients for Krebs Cycle Altered Cancer

NCT05904457 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

32

Enrollment

OTHER

Sponsor class

Conditions

Solid Tumors
Advanced Solid Tumors
Metastatic Cancer

Interventions

DRUG: bevacizumab
DRUG: erlotinib

Sponsor

Asan Medical Center

Collaborators

[object Object]
[object Object]